Benign Prostatic Hyperplasia News and Research

RSS

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Urodynamix Technologies reviews strategic alternatives for sale of company's assets

Urodynamix Technologies Ltd. today announces that its Board of Directors has initiated a process to review strategic alternatives including the sale of part of or all of the Company's assets.

10 Dec 2009

Glucose can aid in preventing low sodium levels in patients undergoing prostate surgery

In men undergoing prostate surgery, excessive fluid absorption can lead to dangerously low sodium levels. Adding a small amount of glucose to the irrigation fluid used during surgery can help anesthesiologists to prevent this rare but potentially serious complication, reports a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Urodynamix Technologies announces the publication of AMA's 2010 Current Procedural Terminology

Urodynamix Technologies Ltd. today announced that the American Medical Association (AMA) has published its 2010 Current Procedural Terminology (CPT) codes with additions, changes and deletions of billing codes for all medical specialities including urology.

23 Nov 2009

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

20 Nov 2009

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anabolic agents such as Selective Androgen Receptor Modulators (SARMs) are being sold on the black market for their performance enhancing qualities.

19 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

AbbeyMoor Medical Inc. announced today they have been granted a Category I CPT code by the American Medical Association (AMA) for The Spanner(TM) temporary prostatic stent insertion procedure. This important action, effective in January 2010, upgrades The Spanner from a Category III emerging technology procedure code to a Category I procedure code for established procedures.

15 Oct 2009

Urodynamix Technologies commences uroNIRS 2000 pilot program

Urodynamix Technologies Ltd. today announces that it has commenced a pilot sales and marketing program with Cardinal Health for its uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's catalogue of offerings to the urology market.

8 Oct 2009

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

Impax Laboratories, Inc. today announced that it has reached agreement with Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. to settle pending U.S. litigation with regard to US Patent No. 4,703,063 for FLOMAX® (generic name: tamsulosin hydrochloride) capsules through the entry of a consent judgment confirming the validity and infringement of the patent. FLOMAX® is a treatment for the functional symptoms of benign prostatic hyperplasia.

7 Oct 2009

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. Boehringer Ingelheim Pharmaceuticals, Inc. markets FLOMAX® for the functional symptoms of benign prostatic hyperplasia.

5 Oct 2009

Neurocrine Biosciences enters into an amendment to its facility lease agreement

Neurocrine Biosciences, Inc. announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

5 Oct 2009

Benign Prostatic Hyperplasia News and Research

Eli Lilly provides financial guidance for 2010

Urodynamix Technologies reviews strategic alternatives for sale of company's assets

Glucose can aid in preventing low sodium levels in patients undergoing prostate surgery

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Urodynamix Technologies announces the publication of AMA's 2010 Current Procedural Terminology

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

Urodynamix Technologies commences uroNIRS 2000 pilot program

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Neurocrine Biosciences enters into an amendment to its facility lease agreement

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News